StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$101.46+7.65 (+8.15%)

Close on Nov 18, 2026Market cap $8.95BP/E –Yield –

Spyre Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Spyre Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$208.94M. For fiscal 2025 it was -$169.25M. The highest annual figure on record is -$7.34M in fiscal 2014.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$169.25M–
FY2024Dec 31, 2024-$157.41M–
FY2023Dec 31, 2023-$99.91M–
FY2022Dec 31, 2022-$80.14M–
FY2021Dec 31, 2021-$53.72M–
FY2020Dec 31, 2020-$75.78M–
FY2019Dec 31, 2019-$65.69M–
FY2018Dec 31, 2018-$32.19M–
FY2017Dec 31, 2017-$24.62M–
FY2016Dec 31, 2016-$18.84M–
FY2015Dec 31, 2015-$10.98M–
FY2014Dec 31, 2014-$7.34M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$69.88M–
Q1 FY2026Mar 31, 2026-$57.37M–
Q4 FY2025Dec 31, 2025-$44.58M–
Q3 FY2025Sep 30, 2025-$37.12M–
Q2 FY2025Jun 30, 2025-$46.56M–
Q1 FY2025Mar 31, 2025-$40.99M–
Q4 FY2024Dec 31, 2024-$37.20M–
Q3 FY2024Sep 30, 2024-$29.42M–
Q2 FY2024Jun 30, 2024-$62.25M–
Q1 FY2024Mar 31, 2024-$28.54M–
Q4 FY2023Dec 31, 2023-$31.04M–
Q3 FY2023Sep 30, 2023-$34.60M–
Q2 FY2023Jun 30, 2023-$16.64M–
Q1 FY2023Mar 31, 2023-$17.63M–
Q4 FY2022Dec 31, 2022-$18.14M–
Q3 FY2022Sep 30, 2022-$15.07M–
Q2 FY2022Jun 30, 2022-$20.67M-1092.9%
Q1 FY2022Mar 31, 2022-$26.26M–
Q4 FY2021Dec 31, 2021-$19.27M–
Q3 FY2021Sep 30, 2021-$17.00M–
Q2 FY2021Jun 30, 2021$2.08M–
Q1 FY2021Mar 31, 2021-$19.53M–
Q4 FY2020Dec 31, 2020-$17.13M–
Q3 FY2020Sep 30, 2020-$17.54M–
Q2 FY2020Jun 30, 2020-$19.41M–
Q1 FY2020Mar 31, 2020-$21.69M–
Q4 FY2019Dec 31, 2019-$16.29M–
Q3 FY2019Sep 30, 2019-$17.21M–
Q2 FY2019Jun 30, 2019-$16.38M–
Q1 FY2019Mar 31, 2019-$15.81M–
Q4 FY2018Dec 31, 2018-$7.20M–
Q3 FY2018Sep 30, 2018-$8.50M–
Q2 FY2018Jun 30, 2018-$9.04M–
Q1 FY2018Mar 31, 2018-$7.45M–
Q4 FY2017Dec 31, 2017-$5.87M–
Q3 FY2017Sep 30, 2017-$7.37M–
Q2 FY2017Jun 30, 2017-$5.94M–
Q1 FY2017Mar 31, 2017-$5.43M–
Q4 FY2016Dec 31, 2016-$4.36M–
Q3 FY2016Sep 30, 2016-$5.87M–

More Spyre Therapeutics figures

See a number that looks wrong?